K Chris Min, Walter K Kraft, Phung Bondiskey, Francheska Colón-González, Wen Liu, Jialin Xu, Deborah Panebianco, Lori Mixson, Marissa F Dockendorf, Catherine Z Matthews, Ramesh Boinpally
Atogepant is a potent, selective, oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical structure of atogepant is distinct from previous CGRP receptor antagonists, which were associated with elevated serum alanine aminotransferase (ALT) in clinical trials. Here, we report the safety, tolerability, and pharmacokinetics (PKs) of a once-daily supratherapeutic dose (170 mg) of atogepant for 28 days from a randomized, double-blind, placebo-controlled phase I trial in healthy participants...
March 2021: Clinical and Translational Science